News | February 07, 2026
Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
Hologic has been at the forefront of cervical cancer screening for decades
Hologic has been at the forefront of cervical cancer screening for decades
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
Subscribe To Our Newsletter & Stay Updated
